BioArctic Announces Start of Phase 1 Study of ABBV-0805 for Parkinson’s Disease
BioArctic AB (publ) announced that the first clinical study with ABBV-0805 has started in the U.S. AbbVie is responsible for the clinical development of ABBV-0805. The Phase 1 study in…
Read More...
Read More...
